Wednesday, 17 July 2019

OliX Pharma expands ocular disease pipeline

15 May 2019 | News

Adds OLX304A for the Treatment of Retinitis Pigmentosa

image credit- istock.com

image credit- istock.com

OliX Pharmaceuticals, Inc., a leading developer of RNAi therapeutics in South Korea, announced an expansion of its ocular disease pipeline. Specifically, the company announced that OLX304A has been added to develop an RNAi therapeutic with a novel target (undisclosed) for treatment of Retinitis Pigmentosa (RP) in a presentation at the Investor Relations Meeting in Seoul on May 10th.

OLX304A is a program to develop a treatment that targets a single gene for RP patients regardless of their disease-causing gene mutation. This strategy is different from the conventional treatment development strategies for RP which target individual disease-causing genes.

An IND application of OLX304A program is planned to be submitted to the US FDA to initiate a Phase 1 within the first half of next year.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account



Podcast

 

Survey Box

Is Blockchain offering a solution to the healthcare industry?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls